Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · IEX Real-Time Price · USD
10.52
+0.05 (0.48%)
Nov 30, 2023, 11:52 AM EST - Market open
Theravance Biopharma Revenue
Theravance Biopharma had revenue of $54.51M in the twelve months ending September 30, 2023, with 5.55% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $15.69M with 26.04% year-over-year growth. In the year 2022, Theravance Biopharma had annual revenue of $51.35M, a decrease of -7.17%.
Revenue (ttm)
$54.51M
Revenue Growth
+5.55%
P/S Ratio
9.63
Revenue / Employee
$491,063
Employees
111
Market Cap
524.37M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 51.35M | -3.97M | -7.17% |
Dec 31, 2021 | 55.31M | -16.55M | -23.03% |
Dec 31, 2020 | 71.86M | -1.56M | -2.12% |
Dec 31, 2019 | 73.41M | 13.04M | 21.61% |
Dec 31, 2018 | 60.37M | 44.98M | 292.37% |
Dec 31, 2017 | 15.39M | -33.26M | -68.37% |
Dec 31, 2016 | 48.65M | 6.52M | 15.48% |
Dec 31, 2015 | 42.13M | 30.44M | 260.42% |
Dec 31, 2014 | 11.69M | 11.46M | 5,071.68% |
Dec 31, 2013 | 226.00K | -129.92M | -99.83% |
Dec 31, 2012 | 130.15M | 115.29M | 776.16% |
Dec 31, 2011 | 14.85M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ModivCare | 2.71B |
Enhabit | 1.05B |
Atrion | 168.60M |
Wave Life Sciences | 85.49M |
SomaLogic | 81.72M |
OmniAb | 64.69M |
IRadimed | 62.97M |
Caribou Biosciences | 34.61M |
TBPH News
- 14 days ago - Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System - PRNewsWire
- 15 days ago - Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference - PRNewsWire
- 17 days ago - Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) - PRNewsWire
- 22 days ago - Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update - PRNewsWire
- 6 weeks ago - Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023 - PRNewsWire
- 3 months ago - Theravance Biopharma to Participate in an Upcoming Investor Conference - PRNewsWire
- 3 months ago - Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders - PRNewsWire
- 4 months ago - Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update - PRNewsWire